Research reveals a novel platform for targeted cancer treatment using self-propelled Janus nanomotors, suggesting significant potential in medical applications.
The present research focused on the manufacturing and designing of a magnetic self-propelled theranostic Janus nanomotor for targeted cancer cell diagnosis and treatment. Platinum (Pt)-based magnetite Janus nanomotors were synthesized by the Pickering Janus emulsions method and used as carriers for the chemotherapy drug Doxorubicin (DOX). Nanomotors were functionalized with a folic acid (FA) ligand and two biocompatible and biodegradable polymers, polycaprolactone (PCL) and poly (2-hydroxyethyl methacrylate) (PHEMA), termed Ac/FA-PHEMA-g-PCL MNP. The hydrodynamic diameter, zeta potential, morphology, drug loading capacity and in-vitro release at pH 7.4 and 5.8, MR contrast agent potential, motility, and peroxidase-like activity of the synthesized nanomotors were analyzed. The findings showed their size of 105.275 ± 26.48 nm and zeta potential of -45.63 ± 0.80 mV and proved cellular internalization, the ability of motion and H₂O₂ catalyze, and diagnostic feature by MRI about them. The drug's cumulative release from nanomotors was restricted. Only 37.26% and 49.90% of the encapsulated drug were released within 24 h at 37 °C in neutral and acidic pH levels, respectively. Under hyperthermia, the release also only reached 58.05%. Ac/FA-PHEMA-g-PCL MNP Janus nanomotors were found to be promising platforms for diagnosing and treating cancer cells.
No takes yet. Share an insight, caveat, or question.
Nikfar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: